UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-34951 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delawar ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q4 2020 Earnings Conference Call February 24, 2020 9:00 AM ET Company Participants Matt Steinberg - Lazar FINN Partners Sean Browne - President and CEO Greg Jensen - VP Finance and CFO Conference Call Participants Operator Greetings, and welcome to the Xtant Medical Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I'd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-34951 Xtant Medical Holdings, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-531332 ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q3 2020 Earnings Conference Call October 29, 2020 9:00 AM ET Company Participants David Carey - Lazar FINN Partners Sean Browne - President and CEO Greg Jensen - VP, Finance and CFO Conference Call Participants Operator Greetings, and welcome to the Xtant Medical's Q3 2020 Financial Results. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) | Delaware | 20-5313323 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q2 2020 Results Earnings Conference Call August 3, 2020 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, Associate Vice President at Lazar FINN Partners Sean Browne - President, Chief Executive Officer Greg Jensen - Vice President of Finance, Chief Financial Officer Conference Call Participants Operator Greetings and welcome to Xtant Medical second quarter 2020 financial results conference call. At this time, all participants are in a listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-34951 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2020 was $14.8 million, down from $16.7 million in Q1 2019, primarily due to the impact of COVID-19 and the halt of elective procedures [21] - Gross margin for Q1 2020 was 65.0%, slightly up from 64.6% in the same period a year ago [22] - Net loss for Q1 2020 was $2.5 million or $0.19 per share, compared to a net loss of $2.8 million or $0.21 per share in Q1 2019 [25] Business Line Data and Key Metrics Changes - General and administrative expenses decreased to $4.3 million in Q1 2020 from $4.5 million in Q1 2019, mainly due to lower legal expenses and consulting fees [23] - Sales and marketing expenses were $6.4 million for Q1 2020, down 5% from $6.7 million in Q1 2019, attributed to lower sales commissions due to decreased sales [24] - Research and development expenses were approximately $250,000 for Q1 2020, slightly down from $262,000 in Q1 2019 [25] Market Data and Key Metrics Changes - As of March 31, 2020, the company had $3.2 million in cash and cash equivalents, $9.7 million in net accounts receivable, and $18 million in inventory [26] Company Strategy and Development Direction - The company identified four areas for improvement to emerge stronger from the COVID-19 crisis, including employee safety, cost reduction initiatives, addressing production shortfalls, and optimizing customer management [12][14][16][17] - The company aims to operate as a leaner organization and improve the efficiency of biologics production to fulfill its mission as conditions normalize [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the resumption of elective procedures and the progress made in transforming the organization before the pandemic [18] - The company believes that cost-saving actions in response to the pandemic will help navigate through the current uncertainty [28] Other Important Information - The company has enacted workforce reductions and furloughs, along with pay decreases for all employees and the Board of Directors as part of its cost-saving measures [14] Q&A Session Summary - The Q&A session concluded without any recorded questions or answers, indicating a lack of engagement from participants during this segment [30]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-34951 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delawar ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q4 2019 Earnings Conference Call March 5, 2020 9:00 AM ET Company Participants David Carey - Lazar FINN Partners Sean Browne - President & Chief Executive Officer Greg Jensen - Vice President-Finance & Chief Financial Officer Conference Call Participants Operator Welcome to Xtant Medical's Fourth Quarter and Full Year 2019 Financial Results Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions] As a reminder, this conference ...